Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 1
1992 5
1993 8
1994 11
1995 13
1996 27
1997 9
1998 12
1999 11
2000 21
2001 18
2002 24
2003 25
2004 29
2005 45
2006 33
2007 32
2008 42
2009 63
2010 49
2011 56
2012 70
2013 60
2014 67
2015 78
2016 56
2017 42
2018 45
2019 43
2020 56
2021 33
2022 22
Text availability
Article attribute
Article type
Publication date

Search Results

1,004 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Müller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjöström CD, Jacob S, Seufert J, Dronamraju N, Csomós K. Müller-Wieland D, et al. Diabetes Obes Metab. 2018 Nov;20(11):2598-2607. doi: 10.1111/dom.13437. Epub 2018 Jul 16. Diabetes Obes Metab. 2018. PMID: 29947099 Free PMC article. Clinical Trial.
FPG decreased significantly with dapagliflozin plus saxagliptin compared with glimepiride (-2.1 mmol/L vs -1.5 mmol/L) and was similar with dapagliflozin (-1.6 mmol/L) compared with glimepiride. ...CONCLUSIONS: Dapagliflozin, saxagliptin and metformin improved glyca …
FPG decreased significantly with dapagliflozin plus saxagliptin compared with glimepiride (-2.1 mmol/L vs -1.5 mmol/L) and was simila …
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Lancet Diabetes Endocrinol. 2014. PMID: 24948511 Clinical Trial.
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was -0.11% (95% CI -0.19 to -0.02; p=0.0153 for superiority). Adverse events were reported …
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in Hb …
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Cefalu WT, et al. Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12. Lancet. 2013. PMID: 23850055 Clinical Trial.
We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with metformin. ...For lowering of HbA1c at 52 weeks, canagliflozin 100 mg was non-inferior to glimepiride (least-squa …
We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequat …
[Glimepiride].
Nakamura N. Nakamura N. Nihon Rinsho. 2002 Sep;60 Suppl 9:351-6. Nihon Rinsho. 2002. PMID: 12387017 Review. Japanese. No abstract available.
Pioglitazone hydrochloride/glimepiride.
Blake EW. Blake EW. Drugs Today (Barc). 2007 Jul;43(7):487-97. doi: 10.1358/dot.2007.43.7.1073850. Drugs Today (Barc). 2007. PMID: 17728849 Review.
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines are in place to limit patient selection for the use of pioglitazone based on cardiac risk factors. In general, pioglitazone and glimepir
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S. Yoo H, et al. Drug Des Devel Ther. 2020 Nov 24;14:5179-5187. doi: 10.2147/DDDT.S275343. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33262578 Free PMC article. Clinical Trial.
In this study, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between evogliptin and glimepiride. MATERIALS AND METHODS: A randomized, open-label, 3-period, 3-treatment, 2-sequence crossover study was conducted in healthy male su …
In this study, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between evogliptin and glimepir
Glimepiride-Loaded Nanoemulgel; Development, In Vitro Characterization, Ex Vivo Permeation and In Vivo Antidiabetic Evaluation.
Razzaq FA, Asif M, Asghar S, Iqbal MS, Khan IU, Khan SU, Irfan M, Syed HK, Khames A, Mahmood H, Ibrahim AY, El Sisi AM. Razzaq FA, et al. Cells. 2021 Sep 13;10(9):2404. doi: 10.3390/cells10092404. Cells. 2021. PMID: 34572054 Free PMC article.
Glimepiride (GMP), an oral hypoglycemic agent is extensively employed in the treatment of type 2 diabetes. ...The present study was designed to formulate topical nanoemulgel GMP system and previously reported solubility enhanced glimepiride (GMP/betaCD/GEL-44/16) in
Glimepiride (GMP), an oral hypoglycemic agent is extensively employed in the treatment of type 2 diabetes. ...The present study was d
Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice.
Niedowicz DM, Özcan S, Nelson PT. Niedowicz DM, et al. J Diabetes Res. 2018 Oct 29;2018:1251345. doi: 10.1155/2018/1251345. eCollection 2018. J Diabetes Res. 2018. PMID: 30510962 Free PMC article.
Here, we report the results of studies treating mice with a sulfonylurea (glimepiride) in order to understand how the drug affects glucose homeostasis and tolerance. We tested the effect of glimepiride on fasting blood glucose, glucose tolerance, and insulin secreti …
Here, we report the results of studies treating mice with a sulfonylurea (glimepiride) in order to understand how the drug affects gl …
Clinical review of glimepiride.
McCall AL. McCall AL. Expert Opin Pharmacother. 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. Expert Opin Pharmacother. 2001. PMID: 11336617 Review.
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment of Type 2 diabetes mellitus (DM). Glimepiride therapy ameliorates the relative insulin secretory deficit found in most patients with …
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment …
Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
Park JW, Kim KA, Choi YJ, Yoon SH, Park JY. Park JW, et al. J Clin Pharm Ther. 2019 Oct;44(5):720-725. doi: 10.1111/jcpt.12848. Epub 2019 May 15. J Clin Pharm Ther. 2019. PMID: 31094010
WHAT IS KNOWN AND OBJECTIVE: Teneligliptin is a DPP-4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in combination with glimepiride. Teneligliptin is metabolized by CYP3A4, and glimepiride might be partly metabolized by CYP3A4. .. …
WHAT IS KNOWN AND OBJECTIVE: Teneligliptin is a DPP-4 inhibitor used for the treatment of type 2 diabetes mellitus, commonly prescribed in c …
1,004 results